polymyxin b

Polymyxin B, an antibiotic, combats Gram-negative infections through high-affinity binding to the bacterial wall's lipopolysaccharides (LPS), neutralizing endotoxin effects and inducing bacterial cell death by enhancing permeability. It is utilized in endotoxemia research [1] [3].

Polymyxin B Sulfate (Poly-RX) is a mixture of polymyxins B1 and B2, obtained from Bacillus polymyxa strains. They are basic polypeptides of about eight amino acids and have cationic detergent action on cell membranes. Polymyxin B Sulfate (Poly-RX) is used for infections with gram-negative organisms, but may be neurotoxic and nephrotoxic.

Polymyxin B nonapeptide acetate is a cationic cyclic peptide. Polyxin B nonapeptide is a derivative produced by enzymatic cleavage of polyxin B. Compared with polyxin B, polyxin B nonapeptide has low toxicity, lacks bactericidal activity and still has the

Polymyxin B nonapeptide, a cationic cyclic peptide derived by enzymatic processing from the naturally occurring peptide polymyxin B, is able to increase the permeability of the outer membrane of Gram-negative bacteria toward hydrophobic antibiotics probab

Polymyxin B nonapeptide TFA (catalog number T64687) is a valuable organic compound for life sciences research.

Polymyxin B2, a significant component of polymyxin B, is an antibiotic cationic lipopeptide initially derived from B. polymyxa. This compound effectively inhibits P. aeruginosa, A. baumannii, K. pneumoniae, and E. cloacae strains, exhibiting minimum inhibitory concentrations (MICs) of 1-2, 0.5-1, 0.25-0.5, and 0.25-1 µg/ml, respectively. Notably, in a mouse model of P. aeruginosa bloodstream infection, administration of polymyxin B2 at a dosage of 4 mg/kg has been shown to decrease the number of colony-forming units (CFUs) in the blood.

SPR741 acetate is a cationic peptide derived from polymyxin B. It exhibits antimicrobial activity against gram-negative bacteria by inhibiting severe gram-negative bacterial sensory by increasing the permeability of the outer membrane of gram-negative bacteria.SPR741 acetate is often used in conjunction with antibiotics for the treatment of a number of diseases.

Polymyxin E1, a peptide antibiotic and key component of the cationic lipopeptide antibiotic colistin, was initially extracted from B. polymyxa. It demonstrates effectiveness against P. aeruginosa and E. coli, with minimum inhibitory concentrations (MICs) of 2 µg/ml and 0.8 µg/ml, respectively.

SPR741 TFA (NAB741 TFA) is a cationic peptide derived from polymyxin B and is a potentiator molecule.

SPR741 TFA (NAB741 TFA), a cationic peptide derived from polymyxin B, acts as a potentiator molecule that enhances the permeability of Gram-negative bacteria's outer membrane, thereby facilitating the treatment of severe Gram-negative bacterial infections. This compound effectively inhibits multidrug-resistant Gram-negative bacteria and, when combined with antibiotics, broadens their spectrum of activity [1] [2].

SPR741, formerly NAB741 (12), is a cationic peptide derived from polymyxin B and is one such potentiator molecule that is under development for the treatment of serious Gram-negative bacterial infections.

Polymyxin E2, a key component of the cationic lipopeptide antibiotic colistin, was originally derived from B. polymyxa and serves as a peptide antibiotic. It exhibits effective antibacterial activity against the plant pathogen X. oryzae, with an EC50 value of 0.21 µg/ml, and has been shown to both prevent and mitigate rice bacterial leaf blight in greenhouse experiments at a dosage of 200 µg/ml.

Polymyxin B1-i is a polypeptide antibiotic.

PA3552-IN-1 is an antibiotic adjuvant that can reduce the expression of PA3552 and restore the sensitivity of MDR Pseudomonas aeruginosa DK2 strain to Polymyxin B.

Polymyxin B2 is an antibiotic primarily utilized for resistant Gram-negative infections. It is derived from the bacterium Bacillus polymyxa.

Polymyxin B1, a potent antimicrobial lipopeptide derived from Bacillus polymyxa, has potential for treating multidrug-resistant Gram-negative bacterial infections.

IKD-8344 is a macrocyclic dilactone originally isolated from an actinomycete species with diverse biological activities, including anticancer, antimicrobial, and anthelmintic properties [1,2,3]. It is cytotoxic to L5178Y murine leukemia cells (IC50 = 0.54 ng ml) [1], inhibits growth of the mycelial form of C. albicans (MIC = 6.25 μg ml), and potentiates the activity of polymyxin B against the multidrug-resistant pathogenic bacterium B. cenocepacia [2,3]. Additionally, it is active against T. spiralis in vitro and in vivo [1].